



THE ROLE OF NANOTECHNOLOGY IN DIABETES TREATMENT

Sujay Kisan Chavan¹, Dhanashri Puri², Rani Mehtre³, Vijaysinh Sable⁴

¹Student, Lokmangal College of Pharmacy, Wadala, Solapur, Maharashtra, 413222

²Assistant Professor, Lokmangal College of Pharmacy, Wadala, Solapur, Maharashtra, 413222

³Vice Principal, Lokmangal College of Pharmacy, Wadala, Solapur, Maharashtra, 413222

⁴Principal, Lokmangal College of Pharmacy, Wadala, Solapur, Maharashtra, 413222

Lokmangal College of Pharmacy, Wadala, Solapur, Maharashtra, 413222

Article DOI: <https://doi.org/10.36713/epra24871>

DOI No: 10.36713/epra24871

ABSTRACT

Diabetes mellitus remains one of the most challenging metabolic diseases in the world, largely because of the disease's progressive nature and the shortcomings of existing treatments. Nanotechnology has emerged as a promising tool to address these problems because it provides innovative methods for monitoring, diagnosis, and treatment. Nanocarriers, including injectable and oral systems, have been thoroughly studied for controlled and sustained insulin delivery, as glucose-responsive nanoparticles have demonstrated promise for self-regulated insulin release and extended glycemic control. The accuracy and compliance issues with current methods may be resolved by the development of highly sensitive, real-time glucose monitoring using nanosensors and implantable devices in parallel. Nanomaterials have been investigated for immunomodulation and islet cell encapsulation in addition to glycemic control in order to prolong and improve the survival of transplanted beta-cells. In addition to improving wound healing in the treatment of diabetic issues, nanocarriers have therapeutic potential in the treatment of retinopathy, nephropathy, and neuropathy. Recent advances have brought attention to precision nanomedicine approaches for targeted drug delivery, nucleic acid-based therapies, and integration with state-of-the-art technologies like biosensors and smart delivery platforms. Despite recent progress, translational barriers remain in the areas of safety, large-scale manufacturing, and regulatory concerns. All things considered, the information that is currently available shows how revolutionary nanotechnology can be in the treatment of diabetes, but it also emphasizes the need for extensive testing before widespread clinical use.

KEYWORDS: Nanotechnology; Diabetes; Nanomaterials; Insulin Delivery; Glucose Sensors

INTRODUCTION

Diabetes mellitus is one of the most common chronic diseases in the world, and conventional therapies usually fail to achieve long-term glycemic control or prevent secondary complications. Insulin therapy is required despite the risks of hypoglycemia, irregular absorption, and patient noncompliance [1]. Nanotechnology introduces novel ways to overcome these challenges. Nanoparticle-based systems offer controlled and prolonged insulin release, more closely resembling physiological secretion [1], while glucose-responsive nanoparticles offer self-regulated insulin delivery in response to blood glucose changes [2]. Oral nanocarriers sensitive to pH and reactive oxygen species improve gastrointestinal absorption and insulin stability [6,7]. In glucose monitoring, nanobiosensors provide continuous, fast, and incredibly sensitive detection [3,9]. Furthermore, nanomaterials help treat diabetes sequelae like retinopathy, nephropathy, neuropathy, and poor wound healing [4], enhance islet transplantation [1,8], and support beta-cell protection. Precision nanomedicine that combines biosensors with targeted carriers holds promise for tailored treatment, despite ongoing significant challenges in safety, scalability, and regulatory approval [1,5,10].

NANOTECHNOLOGY IN DIABETES MANAGEMENT: CURRENT ADVANCES

The use of nanotechnology in diabetes research has advanced significantly in recent years, with solutions that tackle the primary problems of glucose monitoring, insulin administration, beta-cell protection, and complication treatment. Collectively, these advancements demonstrate how nanoscale engineering is transforming medical practices.

• Insulin and Drug Delivery Systems

Nanoparticle-based formulations are now an essential part of diabetes nanomedicine. These carriers provide controlled and sustained insulin release that is more like endogenous secretion than conventional injections [1]. One significant advancement is glucose-responsive nanoparticles, which release insulin in response to glucose fluctuations, thereby enabling self-regulated glycemic control in vivo [2]. These systems reduce the risk of hypoglycemia and improve overall stability. Additionally, nanotechnology has enhanced the oral administration of insulin. For example, dual-sensitive nanoparticles that respond to pH and reactive oxygen species improve intestinal absorption and protect insulin from enzymatic breakdown in the gastrointestinal tract [6]. Similarly, carriers of micro- and



nanoparticles have been shown to improve the stability and bioavailability of oral insulin, providing a viable alternative to injectable therapy [7]. Together, these advancements represent a major step toward reducing the discomfort associated with daily insulin injections.

- **Glucose Monitoring and Biosensors**

For the management of diabetes, accurate glucose monitoring is crucial. Nanotechnology has enabled the creation of nanosensors with high sensitivity, specificity, and fast response times [3]. These sensors outperform traditional enzymatic assays by minimizing patient discomfort and offering continuous real-time monitoring. Implantable nanosensors, which hold promise for seamless integration into closed-loop insulin administration systems, further expand this development [9]. These techniques could pave the way for automated "artificial pancreas" systems that combine real-time monitoring and on-demand insulin release.

- **Islet Cell Protection and Regeneration**

Another fascinating application of nanomaterials is in islet transplantation and beta-cell protection. Encapsulation techniques create nanoscale barriers that allow for adequate oxygen and nutrition exchange while shielding transplanted beta cells from immune rejection [1]. Additionally, nucleic acid-based nanocarriers have been used to deliver therapeutic RNAs or DNAs that change gene expression and protect beta cells from apoptosis, thereby promoting functional recovery [8]. These strategies are especially relevant to type 1 diabetes because one of the main challenges is still the autoimmune destruction of beta cells.

- **Microneedle Patches for Transdermal Delivery**

Microneedle-based patches, which combine minimal invasiveness and continuous drug delivery, are another innovative advancement. A closed-loop dual-hormone microneedle patch that delivered both insulin and glucagon in response to glucose changes, thereby providing strict glycemic control in experimental mice, was described [5]. Glucose-responsive microneedle patches with long-acting insulin delivery capabilities that addressed the challenge of maintaining stable glucose levels over extended periods were also demonstrated [14].

According to these studies, microneedle technologies have the potential to be used in integrated, closed-loop diabetes management in addition to improving patient comfort by preventing the need for repeated injections.

- **Gene and cell - Based Therapies with Nanotechnology**

Beyond drug delivery and monitoring, nanotechnology helps with gene-based and regenerative diabetes treatments in addition to medication administration and tracking. Nanocoatings can lengthen the graft life by protecting transplanted islets from immunological rejection [1]. Nanocarriers have also been advanced in gene delivery, specifically for β -cell regeneration and immune response control [15]. This field is still primarily experimental, but nanotechnology may eventually help with disease-modifying treatments rather than just symptomatic management.

- **Management of Diabetic Complications**

In addition to regulating blood sugar, nanotechnology can help with the complications of diabetes. By increasing angiogenesis, decreasing infection, and speeding up tissue regeneration, nanoparticle-based treatments aid in wound healing [4]. Targeted nanocarriers are being investigated for the treatment of microvascular conditions like diabetic retinopathy, nephropathy, and neuropathy in addition to wound care. These applications demonstrate how nanomedicine can be used to treat diseases at different stages.

- **Toward Precision Nanomedicine**

Recent assessments indicate that nanotechnology is promoting precise and individualized care. Targeted nanocarriers reduce systemic adverse effects by facilitating site-specific drug release [5]. While the delivery of nucleic acids opens the door to genetic interventions, the combination of intelligent delivery systems and nanosensors enables responsive and adaptive therapy [8]. These platforms are integrated into more comprehensive plans to produce multipurpose systems that can treat, monitor, and diagnose patients with a single tool or formulation [10]. This confluence is a critical step in future diabetes management.

- **Critical Evaluation and Translational Outlook**

There are still a lot of problems in spite of some positive developments. studied significant topics like long-term safety of nanomaterials, reproducibility of large-scale manufacturing, and regulatory ambiguity [7]. [2, 3] have pointed out that while glucose-responsive systems work effectively in animal models, managing immunological reactions and inter-individual heterogeneity in humans requires intensive testing. However, the outlook remains positive. [15] claimed that integrating wearable biosensors, artificial intelligence, and digital health platforms with nanotechnology could hasten the development of fully automated, personalized diabetic care systems.

- **Challenges and Considerations**

Despite significant progress, a number of challenges need to be addressed before nanomedicine can be fully integrated into clinical practice. Large-scale, repeatable manufacturing processes are required for clinical translation, and issues with the potential toxicity and long-term safety of nanomaterials must be resolved [1,5]. Regulatory frameworks must also evolve to assess the complexity of products involving nanomedicine. These limitations must be addressed if the clinical potential of these discoveries is to be fully realized.

In conclusion, nanotechnology has significantly improved beta-cell protection, insulin delivery, glucose monitoring, and complication management. The trend toward precision nanomedicine suggests that diabetes treatment will become more successful, automated, and individualized in the future. Ongoing studies focused on safety, scalability, and clinical validation will determine how soon these lab successes translate into widespread patient benefit.




Figure 1. Nanotechnology uses in diabetes detection and treatment (SLNs = Solid Lipid Nanoparticles, NPs = Nanoparticles). [16]

COMPARATIVE EVALUATION OF NANOTECHNOLOGY: BASED APPROACHES WITH CONVENTIONAL THERAPIES

Continuous glucose monitoring (CGM) devices, oral hypoglycemic medications, and numerous daily insulin injections have historically been the mainstays of diabetes treatment. While these techniques remain effective in reducing hyperglycemia and preventing complications, they are often associated with issues like poor patient compliance, hypoglycemia risk, and their limited ability to mimic the body's natural insulin production. Nanotechnology has provided creative solutions to many of these problems. Based on information from ongoing research, this section contrasts and compares medicines based on nanotechnology with traditional treatments.

• Conventional Insulin Therapy versus Nanoparticle-Based Delivery

Insulin injections administered subcutaneously are still used to treat patients with type 1 diabetes and advanced type 2 diabetes. However, injections are uncomfortable and invasive, and they do not provide the exact glycemic control that results from physiological insulin production. Repeated injections may result in localized side effects like lipodystrophy in addition to poor adherence.

Nanoparticle-based systems get around these restrictions by delivering insulin in a controlled, long-lasting, and sometimes oral way. Insulin can be encapsulated by dendrimers, liposomes, and polymeric nanoparticles, which extend its circulation time and protect it from enzymatic degradation [1]. An oral nanotherapeutic insulin formulation that improved intestinal absorption and demonstrated more reliable glycemic outcomes than conventional oral methods, which typically dissolve before absorption, was developed [6]. In a similar vein, dual-coated nanoparticles enhanced insulin stability in gastrointestinal environments, demonstrating superiority over direct oral insulin pills that failed in earlier clinical trials [8].

These findings suggest that, even though injections are still reliable, insulin therapy may develop into a less intrusive, more physiological therapeutic approach that reduces patient stress.



- **Smart Insulin Delivery versus Fixed-Dose Injections**

Traditional insulin therapy requires manual dose adjustments, often with the help of fingerstick glucose testing. This stringent approach increases the risk of both hyperglycemia and hypoglycemia because insulin levels cannot dynamically adjust to changes in glucose levels.

Nanotechnology has enabled glucose-responsive insulin devices, which only release the hormone when blood glucose levels rise. Glucose-responsive nanoparticles were developed to enable rapid and continuous insulin release in hyperglycemic conditions [2]. Cross-species adaptation is a benefit that standard insulin does not have because glucose-responsive polymeric complexes have been shown to function well in both mice and pigs [3]. Moreover, molecularly sensitive insulin analogs were developed that work similarly to "smart insulin" and react proportionately to changes in blood glucose levels [11].

Compared to fixed-dose injections, these nanotechnology-driven systems reduce the frequency of dosing, lower the risk of hypoglycemia, and offer the option of self-regulating treatment, bringing therapy closer to an artificial pancreas model.

- **Microneedle Patches versus Syringe and Pen Injections**

Despite their widespread use, insulin pens and syringes cause discomfort for patients due to repeated skin punctures. Children and elderly patients have the most trouble with compliance.

Microneedle patches are a less invasive option. A closed-loop microneedle system that delivers both insulin and glucagon, allowing for dynamic glycemic regulation superior to traditional injections, has been demonstrated [5]. Glucose-responsive microneedle patches that release insulin gradually and lessen the need for frequent dosage have also been shown [14]. Traditional pens and syringes, on the other hand, do not offer sustained release and must be used multiple times daily.

Thus, microneedle platforms combine efficacy with improved patient experience, offering a potential leap forward in adherence and glycemic stability.

- **Nanosensors versus Conventional Glucose Monitoring**

Subcutaneous sensors used in traditional CGM devices provide blood glucose readings every few minutes. Despite their effectiveness, these devices have drawbacks like skin irritation, frequent calibration, and lag time between interstitial and blood glucose.

Glucose monitoring based on nanotechnology has several benefits. Nanosensors composed of graphene, quantum dots, and gold nanoparticles have been reported to offer greater sensitivity and shorter lag times [1]. Wearable and implantable devices are also better suited for closed-loop systems when responsive insulin delivery and nanosensor integration are combined (Yang et al. [12]). Conventional CGMs still require user input and lack this reactivity even though they are now clinically available.

This comparison highlights that nanosensors could overcome the limitations of current glucose monitoring by enabling seamless, real-time control integrated into therapeutic systems.

- **Nanotechnology in Gene and Cell Therapy versus Current Standard of Care**

Conventional therapies focus on symptom management rather than addressing the root causes of diabetes, such as β -cell dysfunction and autoimmunity.

Novel therapeutic approaches are made possible by nanotechnology. Protective nanocoatings can be used to increase the survival of transplanted islets by preventing immunological rejection [1]. Gene delivery nanocarrier devices have also been developed to affect immunological pathways and promote β -cell regeneration [15]. These strategies contrast sharply with conventional therapies, which do not aim to boost the body's natural insulin production. Although still in the experimental stage, nanotechnology-based gene and cell therapies represent a paradigm shift from lifetime management to potential long-term remission.

- **Limitations and Challenges Compared to Conventional Methods**

Despite these advantages, medications utilizing nanotechnology face difficulties not present in conventional approaches. There is ongoing discussion regarding the long-term safety and large-scale reproducibility of nanomaterials [7]. Traditional insulin injections and CGMs are widely accessible, affordable, and well-established despite these drawbacks. On the other hand, most nanotechnology systems are still in the preclinical or early clinical stage, and manufacturing and regulatory concerns are delaying their widespread use [2, 3, 15].

Therefore, conventional methods continue to have advantages in terms of availability, affordability, and established safety profiles, even though nanotechnology exhibits superior functionality.

**Table : Nanocarriers in Drug Delivery for Diabetes Management**

Nanocarrier Type	Mechanism/ Functional Design	Advantages Over Conventional Delivery	Limitations / Challenges	Key References
Polymeric Nanoparticles	Encapsulation Of insulin and Drug protect against enzymatic degradation; sustained release	Enhanced stability and Prolonged circulation improved glycemic control	Long term Safety and Large scale reproducibility	[1]
Glucose Responsive Polymeric Complexes	Polymers with glucose oxidase or Phenylboronic acid that trigger insulin release in response to glucose	Self regulated insulin delivery, Reduced hypoglycemia, Closer mimicry Of physiology	Enzyme stability Issues, Translation from animals remains limited	[2,4]
Dual-Coated Alginate/Dextran Sulfate Nanoparticles	Oral carriers With dual Coatings to Withstand gastric degradation and enhance absorption	Improved oral Bioavailability and protection from acidic PH	Need optimization For human GI variability	[8]
Multifunctional Oral Nanoparticles	Mucoadhesive and PH sensitive Formulations For intestinal absorption	Strong potential for oral insulin Delivery, Improved stability in GI tract	Clinical validation lacking, Scalability issues	[9,10]
Microneedle Patches with Nanocarriers	Nanoparticle Coated microneedles delivering insulin	Minimally Invasive, long Acting and patient friendly	Manufacturing Challenges, Patient acceptability in long term	[5,14]
Islet Protective Nanocoatings	Nano-Shielding for transplanted β -cell or islets	Reduces Immune rejection and Prolongs graft survival	Experimental Stage, ethical and regulatory concerns	[1,15]

CHALLENGES AND LIMITATIONS

Despite promising advancements in nanotechnology for diabetes treatment, several barriers prevent its widespread application beyond laboratory settings. Two important concerns with nanoparticles are their safety and biocompatibility. Because extended exposure can cause cytotoxicity, immunological reactions, or accumulation in organs, thorough preclinical safety evaluations are required [1,5]. Because various materials, including polymers, lipids, and inorganic nanoparticles, present varying toxicity risks, material selection is essential for clinical translation [1].

Two other important limitations are large-scale production and reproducibility. Even though many nanoparticle formulations work fairly well in small-scale laboratory experiments, scaling up for dependable, high-quality production is difficult. Differences in particle size, surface characteristics, and functionalization may affect regulatory approval and therapeutic efficacy [5]. Concerns about ethics and regulations also present challenges. The combination of drug, device, and biological therapy components in nanomedicine complicates evaluation procedures. Regulatory frameworks for assessing safety, efficacy, and long-term outcomes are still being developed, and there are currently few established standards for nanomedicine in diabetes [1, 5].

Moreover, storage and stability of nanocarriers remain challenging. Particularly oral insulin nanoparticles or glucose-responsive systems, some formulations may lose their therapeutic value over time or under various environmental conditions [6,7]. Finally, patient-specific variability must be addressed. Individual differences in immunological response, metabolism, and gastrointestinal



absorption can impact the effectiveness of treatments based on nanoparticles, highlighting the need for customized approaches [5,10].

In conclusion, challenges related to patient variability, safety, scalability, stability, and regulatory oversight must be addressed even though nanotechnology presents ground-breaking potential for the treatment of diabetes. Thorough preclinical research, standardized production methods, and carefully thought-out clinical trials are required to overcome these limitations and transform these exciting concepts into safe, effective, and widely accessible treatments [1,5].

CONCLUSION

Nanotechnology has emerged as a transformative approach in diabetes management, offering innovations in insulin delivery, glucose monitoring, beta-cell protection, and treatment of complications. Glucose-responsive nanoparticles, oral formulations, and nanosensors enable more precise, controlled, and patient-friendly therapies. Encapsulation and nucleic acid-based nanocarriers support beta-cell survival and function, while targeted nanomedicine addresses complications such as wounds, retinopathy, and nephropathy. Despite challenges in safety, scalability, and regulatory approval, continued research promises to advance precision, personalized, and integrated nanomedicine strategies, ultimately improving clinical outcomes for patients with diabetes.

REFERENCES

1. Veisheh O, Tang BC, Whitehead KA, Anderson DG, Langer R. *Managing diabetes with nanomedicine: challenges and opportunities*. *Nature Reviews Drug Discovery*. 2015 Jan;14(1):45-57.
2. Volpatti LR, Matranga MA, Cortinas AB, Delcassian D, Daniel KB, Langer R, Anderson DG. *Glucose-responsive nanoparticles for rapid and extended self-regulated insulin delivery*. *ACS nano*. 2019 Nov 25;14(1):488-97.
3. DiSanto RM, Subramanian V, Gu Z. *Recent advances in nanotechnology for diabetes treatment*. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. 2015 Jul;7(4):548-64.
4. He Y, Al-Mureish A, Wu N. *Nanotechnology in the treatment of diabetic complications: a comprehensive narrative review*. *Journal of Diabetes Research*. 2021;2021(1):6612063.
5. Caturano A, Nilo R, Nilo D, Russo V, Santonastaso E, Galiero R, Rinaldi L, Monda M, Sardu C, Marfella R, Sasso FC. *Advances in nanomedicine for precision insulin delivery*. *Pharmaceuticals*. 2024 Jul 15;17(7):945.
6. Li M, Wang N, Liu R, Zhang X, He W, Zhang W, Li J, Peng C, Li Y. *pH and H₂O₂ dual-sensitive nanoparticles enable enhanced and safe glucose-responsive oral insulin delivery for diabetes mellitus treatment*. *Theranostics*. 2024 Sep 3;14(14):5596.
7. Romero-Carmona CE, Chávez-Corona JI, Lima E, Cortés H, Quintanar-Guerrero D, Bernad-Bernad MJ, Ramos-Martínez I, Peña-Corona SI, Sharifi-Rad J, Leyva-Gómez G. *Nanoparticle and microparticle-based systems for enhanced oral insulin delivery: A systematic review and meta-analysis*. *Journal of Nanobiotechnology*. 2024 Dec 29;22(1):802.
8. Mendes BB, Coniot J, Avital A, Yao D, Jiang X, Zhou X, Sharf-Pauker N, Xiao Y, Adir O, Liang H, Shi J. *Nanodelivery of nucleic acids*. *Nature reviews Methods primers*. 2022 Apr 14;2(1):24.
9. Luo XM, et al. *Nanomedicine for the treatment of diabetes-associated conditions: oral and sustained-release strategies*. *Review*, 2021.
10. Lemmerman LR, Das D, Higuera-Castro N, Mirmira RG, Gallego-Perez D. *Nanomedicine-based strategies for diabetes: Diagnostics, monitoring, and treatment*. *Trends in Endocrinology & Metabolism*. 2020 Jun 1;31(6):448-58.
11. Zeng Y, Wang J, Gu Z, Gu Z. *Engineering glucose-responsive insulin*. *Medicine in Drug Discovery*. 2019 Sep 1;3:100010.
12. Yang J, Cao Z. *Glucose-responsive insulin release: analysis of mechanisms, formulations, and evaluation criteria*. *Journal of Controlled Release*. 2017 Oct 10;263:231-9.
13. Xi Z, Ahmad E, Zhang W, Li J, Wang A, Wang N, Zhu C, Huang W, Xu L, Yu M, Gan Y. *Dual-modified nanoparticles overcome sequential absorption barriers for oral insulin delivery*. *Journal of Controlled Release*. 2022 Feb 1;342:1-3.
14. He Y, Chen N, Zang M, Zhang J, Zhang Y, Lu H, Zhao Q, Mao Y, Yuan Y, Wang S, Gao Y. *Glucose-responsive insulin microneedle patches for long-acting delivery and release visualization*. *Journal of Controlled Release*. 2024 Apr 1;368:430-43.
15. Andreadi A, Lodeserto P, Todaro F, Meloni M, Romano M, Minasi A, Bellia A, Lauro D. *Nanomedicine in the Treatment of Diabetes*. *International Journal of Molecular Sciences*. 2024 Jun 27;25(13):7028.
16. Mandal D, Sarmah JK, Gupta J. *NanoRevolution: pioneering applications of nanotechnology in type II diabetes care*. *Engineering Proceedings*. 2023 Oct 26;56(1):56.